Skip to content
Screener

Evolus EOLS Business Segments — SG&A

Similar metrics at other companies

Indivior Pharmaceuticals, Inc. logo
INDVReportable Segment — SG&A
$124M-6.8%
VGN
VGNTReportable Segment — SG&A
$97M-7.6%
QXO, Inc. logo
QXOReportable Segment — SG&A
$457.8M+1,792%
Agios Pharmaceuticals logo
AGIOReportable Segment — SG&A
$51.55M+12.4%
ITG
ITGRReportable Segment — SG&A
$52.94M+14.3%
Krystal Biotech, Inc. logo
KRYSReportable Segment — SG&A
$41.01M+25.6%

Other financials

Income statement

See full
Revenue$84.1M+21.2%
Gross profit$57.2M+26.2%
Operating income-$4.5M+55.5%
Net income-$8.1M+53.0%
EPS (diluted)-$0.12+55.6%

Balance sheet

See full
Cash & equivalents$45.2M-26.8%
Total debt$164.8M+12.3%
Total equity-$30.9M-65.7%
Total assets$248.0M+8.4%

Cash flow

See full
Operating cash flow-$3.6M+85.5%
CapEx$50.0K-92.7%
Free cash flow-$3.6M+85.7%

Valuation

See full
Market cap$500M+31.0%
Enterprise value$619.64M+32.8%
P/S1.6×+0.2×

Profitability

See full
Gross margin66.7%-0.4pp
Operating margin-13.7%-1.9pp
Net margin-10.9%-3.7pp
FCF margin-9.6%-3.6pp

Returns & leverage

See full
Return on equity-472.6%-1,534pp
Debt / equity22.2×
Current ratio1.7×-0.6×

Where this comes from

Reported directly by Evolus in its filing.

Tagged under the XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense.

The source filing: Evolus’s 10-Q, filed August 5, 2026.

Filed
Aug 5, 2026, 4:56 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001628280-26-053468
Line itemThree Months Ended June 30, 2026Three Months Ended June 30, 2025Six Months Ended June 30, 2026Six Months Ended June 30, 2025
Gross profit57,18045,320106,07791,975
Less:
Research and development1,8921,8374,1324,049
Selling, general and administrative57,05256,675109,033113,315
Depreciation and amortization1,5299323,0671,756
Interest income(296)(479)(581)(1,189)
Interest expense4,1727,2078,14711,622
Income tax (benefit) expense(154)53102125

Item 1. Condensed Consolidated Financial Statements (unaudited)

FAQ

What is Evolus's business segments — SG&A?
Evolus (EOLS) reported business segments — SG&A of $57.05M in Q2 2026.
How has Evolus's business segments — SG&A changed year-over-year?
Evolus's business segments — SG&A increased by 0.7% year-over-year, from $56.68M to $57.05M.
What is the long-term trend for Evolus's business segments — SG&A?
Over 3 years (2022 to 2025), Evolus's business segments — SG&A has grown at a 18.9% compound annual growth rate (CAGR), from $131.28M to $220.79M.
What does business segments — SG&A mean?
Encompasses the operating costs required to support the segment's commercial activities, including sales force compensation, marketing campaigns, and general administrative overhead. This is a key measure of the segment's operational scale and the efficiency of its go-to-market strategy.

Ask your AI about Evolus's business segments — sg&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude